ArticleFrontiers in pharmacology2025
Sex-specific risk signals and onset patterns of drug-induced peripheral neuralgia: a 20-year pharmacovigilance analysis based on FAERS real-world dat.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Adverse events associated with tirzepatide: a focus on subgroup-specific differences.BMC pharmacology & toxicology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Peripheral neuralgia is a chronic pain syndrome resulting from peripheral nerve damage and has been increasingly linked to certain drugs, leading to drug-induced peripheral neuropathy (DIPN). While the neurotoxic potential of many drugs has been recognized, the gender-specific patterns of DIPN remain insufficiently studied. Objective: To identify potential drug safety signals associated with DIPN and explore gender-based differences in risk using real-world pharmacovigilance data. Methods: This retrospective pharmacovigilance study utilized the FDA Adverse Event Reporting System (FAERS) database from 2004 to 2024. Disproportionality analysis (DPA), specifically Reporting Odds Ratio (ROR), was applied to detect associations between drugs and DIPN. Drug and adverse event terms were standardized using RxNorm and MedDRA dictionaries. Weibull distribution modeling was employed to analyze time-to-onset (TTO) characteristics of high-risk drugs in male and female populations. Results: A total of 21,609 adverse event reports of DIPN were analyzed, showing a continuous increase in reporting over two decades. Seventy-two drugs were identified as having potential DIPN risk signals, with 25 drugs showing strong associations after statistical adjustments. Among them, adalimumab, ciprofloxacin, and lenalidomide had the highest number of reports. Eighteen drugs presented new risk signals not previously mentioned in official drug labeling. Gender-specific analysis revealed 49 risk drugs in females, 32 in males, with 23 drugs overlapping. Time-to-onset analysis showed most adverse events occurred early in treatment, as indicated by Weibull shape parameters (β < 1) for all major drugs. Conclusion: This study revealed novel and sex-specific DIPN risk signals using large-scale real-world data. It highlights the importance of early monitoring of neurotoxic effects during drug treatment and provides strong support for implementing gender-sensitive pharmacovigilance strategies and individualized medication risk management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.